Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127252151 | 12725215 | 1 | I | 20101027 | 20160902 | 20160908 | 20160908 | PER | US-CELGENEUS-USA-2016091023 | CELGENE | 58.04 | YR | Y | 0.00000 | 20160908 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127252151 | 12725215 | 1 | PS | THALOMID | THALIDOMIDE | 1 | Oral | 100 MILLIGRAM | U | U | 20785 | 100 | MG | CAPSULES | QD | ||||
| 127252151 | 12725215 | 2 | SS | ALKERAN | MELPHALAN | 1 | Unknown | U | U | 0 | UNKNOWN |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127252151 | 12725215 | 1 | Plasma cell myeloma |
| 127252151 | 12725215 | 2 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127252151 | 12725215 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127252151 | 12725215 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127252151 | 12725215 | 1 | 20100524 | 20101011 | 0 | |
| 127252151 | 12725215 | 2 | 20101019 | 20101019 | 0 |